Patients with type-2 diabetes have an FDA-approved medication option that will help reduce blood sugar levels in conjunction with diet and exercise. Sodium-glucose Cotransporter-2 (SGLT2) inhibitors, including canagliflozin, dapagliflozin, and empagliflozin, affect the function of the proximal tubules in the kidneys which helps block glucose reabsorption. The excess sugars are then released through the urine (glucosuria), effectively lowering overall blood glucose levels.
Type-2 diabetics can be prescribed SGLT2 inhibitors as a single ingredient therapy, or have it combined with other therapies like metformin. The FDA has not yet approved these drugs for use in type-1 diabetes patients.
Juan Pablo Frias, MD
President & CEO: National Research Institute